Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer

Supporting evidence

• Evaluation report

• Appraisal consultation 1 committee papers (PDF 12.35 MB)

  Published:

  20 March 2019

• Appraisal consultation 2 committee papers  (PDF 2.42 MB)

  Published:

  20 March 2019

• Final appraisal determination committee papers (PDF 2.37 MB)

  Published:

  20 March 2019